Search research articles
Contact Us
Filters
Showing results (731-740 of 839) with videos related to
Page
of 84
Sort By:
The Lancet. Oncology
|
October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Cancer Discovery
|
June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway
Pietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
JTO Clinical and Research Reports
|
November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Page
of 84
Search research articles
Search
Showing results (731-740 of 839) with videos related to
Sort By:
Page
of 84
The Lancet. Oncology
|
October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Cancer Discovery
|
June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway
Pietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
JTO Clinical and Research Reports
|
November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Page
of 84